Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US
Viruses · 28.02.2026 · 18 (3) · 299
DOI: 10.3390/v18030299 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 28.02.2026. Verfasst von Thomas C S Martin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: Machine Learning, Cost-Benefit Analysis, Cost-Effectiveness Analysis, Hepatitis C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Gilead Sciences (United States), Gilead.
Abstract (Originalsprache)
Machine learning (ML) algorithms may be effective at improving the HCV care cascade. One ML algorithm, developed using U.S. ambulatory electronic medical records (EMR), demonstrated the ability to identify people infected with HCV earlier than conventional testing strategies among those with indications for screening. We evaluated the potential cost-effectiveness of ML-enabled screening for the early identification of undiagnosed HCV among people in care in the U.S. An HCV natural history Markov model was developed to evaluate the cost-effectiveness of the ML algorithm-enabled screening compared to conventional testing over the training data period. Based on the training data, the ML algorithm identified patients on average 6.5 months earlier than conventional testing strategies. We compared the status quo to intervention scenarios using the ML algorithm at different recall levels (proportion of HCV patients identified, 5–100%). We identified the optimal algorithm recall level, which maximized health (measured in quality-adjusted life years, QALYs) while staying under a willingness-to-pay threshold of USD$100,000/QALY gained. ML-enabled screening was cost-effective (ICER < $100 k/QALY gained) in identifying undiagnosed HCV patients for recall levels up to 30%. The optimal recall level was 30% (Precision 0.27%), which resulted in a mean ICER of $94,022/QALY gained. ML-enabled screening for the early identification of undiagnosed HCV patients could be cost-effective in the U.S. Prospective evaluation of real-world effectiveness is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92093, USA.
- IQVIA, Copenhagen 2200, Denmark.
- Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ 85004, USA.
ORCID-Profile: Thomas C S Martin, Susan J Little
Förderung
- NIAID NIH HHS
- Gilead Sciences (United States)
- Gilead
- NIH
- University of California San Diego Center for AIDS Research
Zitieren
APA
Martin, T. C. S., Wilson, J., Pitcher, A., Frankeberger, J., Little, S. J., & Martin, N. K. (2026). Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US. Viruses, 18(3), 299. https://doi.org/10.3390/v18030299
Vancouver
Martin TCS, Wilson J, Pitcher A, Frankeberger J, Little SJ, Martin NK. Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US. Viruses. 2026;18(3):299. doi:10.3390/v18030299
BibTeX
@article{Martin2026,
author = {Martin, Thomas C S and Wilson, Jeremiah and Pitcher, Ashley and Frankeberger, Jessica and Little, Susan J and Martin, Natasha K},
title = {Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US},
journal = {Viruses},
year = {2026},
volume = {18},
number = {3},
pages = {299},
doi = {10.3390/v18030299}
}
EUVIMED